Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Inclusion Criteria:

* Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.
* Premature or scheduled termination of standard therapy
* Progressive disease as clinically assessed by the investigator
* Max. tumour lesion ≤ 5 cm
* Adequate organ function
* Ability of patient to understand character and individual consequences of clinical trial
* Age ≥ 18 years
* Written informed consent must be available before any study specific procedure is performed

Exclusion Criteria:

* Patients with severe heart diseases
* Clinical significant ischemic disease during the last 4 weeks before Visit 1
* Severe lung disease
* Symptomatic peritoneal carcinomatosis
* Symptomatic pleural or pericardial effusion
* Serious uncontrolled acute infections less than 3 weeks before Visit 1
* Known dependency on alcohol or other drugs
* Patients requiring corticoids in doses above the Cushing threshold
* Known liver fibrosis or liver cirrhosis
* Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator
* Female patient who is pregnant or breast feeding
* Participation in another clinical trial or observation period, respectively, during the last 4 weeks prior to the first IMP dose